Astellas Pharma, Toyama Chemical Agree on Joint Development of Quinolone Antibiotic T-3811 in Japan.Tokyo, Japan, Jan 27, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Astellas Pharma Astellas Pharma Inc. (アステラス製薬株式会社 and Toyama Chemical jointly announced on January 26 that they have reached a basic agreement to collaborate in the development and sales of T-3811, Toyama Chemical's proprietary agent, in Japan. Under the agreement terms, the two companies will jointly develop an oral preparation of T-3811. In addition, Astellas Pharma will make an upfront and milestone payments to Toyama Chemical. The two companies aim to sign an official licensing agreement by March 31. A new type of quinolone antibiotic antibiotic, any of a variety of substances, usually obtained from microorganisms, that inhibit the growth of or destroy certain other microorganisms. Types of Antibiotics , T-3811 has a wide antibacterial antibacterial /an·ti·bac·te·ri·al/ (-bak-ter´e-al) destroying or suppressing growth or reproduction of bacteria; also, an agent that does this. an·ti·bac·te·ri·al adj. spectrum and beneficial effects on gram-positive bacteria. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion